Therefore, the knowledge of the pathological interactions between menin and KMT2A in KMT2Ar leukemias and NPM1mut AML, as well as the underlying mechanism of action analyzed above, has led to the recognition of a new promising target for therapies in this subset of leukemias. This evidence concerns the gene KMT2A and leukemia.